Glaucoma combo solution earns preliminary approval

May 15, 2005

The FDA has issued an approvable letter for the fixed combination of travoprost 0.004% and timolol 0.5% ophthalmic solution (Extravan) for the treatment of glaucoma, according to Alcon Laboratories, its manufacturer.

The FDA has issued an approvable letter for the fixed combination of travoprost 0.004% and timolol 0.5% ophthalmic solution (Extravan) for the treatment of glaucoma, according to Alcon Laboratories, its manufacturer.

The company said it would meet with the FDA to clarify what steps are yet required to gain final marketing approval.